Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): The M. D. Anderson Cancer Center (MDACC) experience.
6060 Background: DTC is a relatively common tumor and about 20% will develop distant metastases (mets) of which at least 50% will not respond to standard tx. Until recently, tx for pts with progressive, RAI negative disease was limited. However, the identification of biologic targets in DTC has led...
| Publicado en: | Journal of Clinical Oncology Vol. 27; pp. 6060 - 6061 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
5/21/2009 Supplement Part 1 of 2
|
| Acceso en línea: | Ver este registro en EBSCOhost |